OncLive TV

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz S. Nowakowski, MD, discusses the rationale for reevaluating the PCKß inhibitor enzastaurin in diffuse large B-cell lymphoma.

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

Jeffrey S. Weber, MD, PhD, discusses emerging therapies in melanoma.

Manfred Welslau, MD, discusses​ the potential benefits of ​using biosimilars in diffuse large B-cell lymphoma.

Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials. 

Anthony B. El-Khoueiry, MD, discusses the frontline treatment landscape of hepatocellular carcinoma.

Mansoor Raza Mirza, MD, discusses the clinical implications of the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Denise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

Joyce F. Liu, MD, MPH, discusses the results of cediranib in combination with olaparib in a phase 3 trial in patients with recurrent platinum-sensitive ovarian cancer.

Toni K. Choueiri, MD, discusses the significance of the COVID-19 and Cancer Consortium during the coronavirus disease 2019 pandemic.

Nilanjan Ghosh, MD, PhD, discusses global trials examining zanubrutinib in mantle cell lymphoma and non-Hodgkin lymphoma.

Jennifer L. Atlas, MD, discusses the ​current cutaneous squamous cell carcinoma treatment paradigm.

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

Nina Shah, MD, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Richard D. Kim, MD, discusses the evolving treatment landscape of advanced hepatocellular carcinoma.

Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.

Ruth O’Regan, MD, discusses emerging CDK4/6 inhibitor combinations in breast cancer.

Anna C. Pavlick, DO, discusses common and uncommon adverse effects with cemiplimab in patients with cutaneous squamous cell carcinoma.

Rana R. McKay, MD, discusses the role of age and gender in advanced renal cell carcinoma outcomes. 

Noam VanderWalde, MD, MS, discusses ​where future research ​efforts should focus in rectal cancer. 

Heather ​S. Han, MD, discusses the importance of pathologic complete response in breast cancer.

Mohammed M. Milhem, MBBS, discusses the design of an open-label, multicenter phase 1b/2 dose escalation/expansion study with AST-008 in combination with a PD-1 inhibitor, such as pembrolizumab or cemiplimab, in Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.

Bradley G. Somer, MD, discusses the clinical implications of the FDA approval of atezolizumab in combination with bevacizumab in unresectable or metastatic hepatocellular carcinoma.

John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.

Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.

Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.

Sara A. Hurvitz, MD, discusses unmet needs within the field of HER2-positive breast cancer.

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.